drug

ARCT-2304

1 story · latest Sep 4, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Arcturus Therapeutics, Inc.

Timeline

Arcturus posts Phase 1/2 results for ARCT-2304 self-amplifying mRNA flu vaccine

Sep 4Trial updateARCT-2304 Arcturus Therapeutics, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.